A. Mantegani

发表

Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection?

C. Mayerat, A. Mantegani, P. Frei, 1999, Journal of viral hepatitis.

Comparison of a competitive combined reverse transcription-PCR assay with a branched-DNA assay for hepatitis C virus RNA quantitation

D. Lavanchy, C. Mayerat, A. Mantegani, 1996, Journal of clinical microbiology.

Mutations in the Basal Core Promoter and Precore/Core Gene of Hepatitis B Virus in Patients with Chronic Active but not Acute Hepatitis B

F. Spertini, C. Mayerat, A. Mantegani, 1999, European Journal of Clinical Microbiology and Infectious Diseases.

Hepatitis C virus (HCV) infection: serum rheumatoid factor activity and HCV genotype correlate with cryoglobulin clonality.

F. Spertini, J. Tissot, C. Mayerat, 1998, Blood.

New heterocyclic systems—I 5,6-dihydro-7H, 12H-dibenz[c,f]azocine

A. Mantegani, G. Pala, E. Zugna, 1970 .

On the healing properties of esters of D-panthenol with terpene acids, with particular reference to D-pantothenyl trifarnesylacetate.

A. Mantegani, G. Coppi, S. Casadio, 1967, Arzneimittel-Forschung.

Terpene compounds as drugs. 11. Anabolic 19-nortestosterone terpenoates.

A. Mantegani, G. Coppi, S. Casadio, 1972, Journal of medicinal chemistry.

Synthesis and pharmacological properties of N-derivatives of 5,7,12,13-tetrahydro-6H-dibenz(c,g)azonine.

S Casadio, G Pala, A Mantegani, 1970, Journal of medicinal chemistry.

[Inflammatory myopathy: unusual presentation of a case of Wegener disease].

J. Aubert, A. Mantegani, G. Guelpa, 1993, Schweizerische medizinische Wochenschrift.

Secondary amines from cyanmides a new method for removing the-CN group

A. Donetti, A. Mantegani, A. Omodei-sale, 1969 .

Hypoglycemic activity of 1-alkenyland 1-alkenoyl-3-arylsulfonylureas.

A. Mantegani, G. Coppi, G. Pala, 1970, Journal of medicinal chemistry.